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The Enteric Diseases Epidemiology Branch (EDEB), Division of Foodborne, Bacterial, and 
Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, is 
responsible for surveillance of bacterial enteric pathogens. National case surveillance 
encompasses two systems administered outside EDEB: the National Notifiable Diseases 
Surveillance System (NNDSS), which is clinical case-based, and the Public Health Laboratory 
Information System (PHLIS), which is a laboratory isolation-based reporting system. The 
laboratory-based system alone includes data on important pathogen characteristics such as 
serotype for Salmonella, Shigella, and Shiga toxin-producing Escherichia coli isolates. 
Serotype information for these pathogens is crucial for surveillance, outbreak detection, and 
investigation. PHLIS also includes some pathogens that are not formally nationally notifiable, 
but may be notifiable at the state level. In addition, EDEB primarily collects information for 
botulism, typhoid fever, cholera, and other Vibrio illnesses, as well as for Shiga toxin-
producing E. coli, non-O157. Information in this report includes case and isolate counts in 2004 
as of November 2006; the numbers may have changed compared with previous publications of 
2004 surveillance data. 
The number of reported cases of diseases under surveillance is a vast underestimate of the true 
burden because most episodes of disease never reach the reporting systems. Many ill persons 
do not seek medical care, medical practitioners may not order the tests to make a specific 
diagnosis, and laboratories may not conduct the appropriate tests to isolate the causative 
pathogens. Some pathogens are not included on the list of nationally notifiable diseases (e.g., 
Campylobacter and Yersinia) and are not included in this report, though individual states may 
require reporting and collect surveillance data. The completeness of surveillance data is 
variable. All reporting from state and territorial departments of public health to the Centers for 
Disease Control and Prevention (CDC) is voluntary. The Foodborne Diseases Active 
Surveillance Network (FoodNet) conducted more intensive surveillance in 10 sites in 2004; 
more information is available at http://www.cdc.gov/foodnet/. 
Many illnesses are not included in any surveillance of individual cases, in part because there 
are no standard clinical tests to detect them. Examples include illnesses due to enterotoxigenic 
E. coli and enterotoxins produced by Bacillus cereus, Clostridium perfringens, and 
Staphylococcus aureus. For such conditions, reports of foodborne outbreak investigations 
provide the best available surveillance information. Foodborne outbreak reports are available at 
http://www.cdc.gov/foodborneoutbreaks/. 
Each year, EDEB summarizes surveillance results in multiple formats, including letters to state 
and territorial epidemiologists and public health laboratory directors, reports in the CDC 
publication Morbidity and Mortality Weekly Report (MMWR), and publications in peer-
reviewed scientific journals. More information about these documents is available at the end of 
this report in the following sections: Sources and Contacts for Bacterial Foodborne and 
Diarrheal Diseases, Publications by Foodborne and Diarrheal Diseases Branch, 2004, and CDC 
Internet Sites Relevant to Foodborne and Diarrheal Diseases. 
This report is the second in an annual series summarizing results from nationally notifiable 
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bacterial foodborne and diarrheal diseases case surveillance systems. A description of the 
surveillance systems is included to explain the differences between these systems and why they 
sometimes have different case counts for the same disease entity (see the Data Sources and 
Background section of this report for more information). The specialized sentinel site 
surveillance system, FoodNet, provides complementary information for a range of foodborne 
infections of public health concern from 10 sites. FoodNet annual summaries are available at 
http://www.cdc.gov/foodnet/reports.htm. 
Looking forward, EDEB is actively involved in advancing the nation’s surveillance for 
foodborne and diarrheal diseases. CDC-wide integrated surveillance systems are under 
construction, which may make national surveillance for many types of diseases more efficient. 
We are working to make more surveillance tools available to state and local public health 
personnel and more surveillance information available to public health workers, policy makers 
and the general public through combined reports and information available on the Internet. 
The case and isolate counts for eight diseases and pathogens for 2004 are presented in Table 1-
1 and described on the following pages. 
5 
Table 1-1. Case and isolate counts for foodborne and diarrheal diseases and pathogens, 2004 
Pathogen/Disease 
Botulism
E. coli O157:H7 
Comments 
 Includes foodborne, 




















E. coli, Shiga toxin-
producing, non-O157
YES 308 139 248 
Hemolytic uremic 
syndrome  YES 200 NA NA 
Listeriosis YES 753 NA NA 
Salmonella Typhi 




serotypes YES 42,197 35,355 NA 
Shigella (shigellosis) Includes 4 subgroups YES 14,627 9,343 NA 
Vibrio cholerae, 
toxigenic 
Includes O1 and O139 
serotypes (that cause 
cholera) and toxigenic 
non-O1, non-O139 V. 
cholerae 
YES 8 NA 8 
Other Vibrios (vibriosis) Some species may not 
be pathogenic 
NO NA NA 479 
* National Notifiable Diseases Surveillance System. 
† Public Health Laboratory Information System. 

§ Enteric Diseases Epidemiology Branch. 

Botulism 
A total of 138 cases of foodborne (14), wound (28), infant (91), and other types (5) of botulism 
were reported to the EDEB botulism surveillance system, including one death (attributed to 
infant botulism) and two outbreaks (defined as two or more cases as a result of persons 
ingesting the same food).  
Escherichia coli O157:H7 and Other Shiga Toxin-Producing E. coli: 
Escherichia coli O157:H7 has been nationally notifiable since 1994. In 2000, the Council for 
State and Territorial Epidemiologists passed a resolution in which all Shiga toxin-producing E. 
coli were made nationally notifiable under the name Enterohemorrhagic Escherichia coli or 
EHEC; national surveillance for EHEC began in 2001. Reported infections with the most well-
known pathogen in this group, E. coli O157:H7, has increased annually since becoming 
nationally notifiable, to a peak of 4,744 in 1999. The steady increase in the number of cases 
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was due in part to an increasing ability of laboratories to identify this pathogen. Coordinated 
efforts by regulators and industry have been effective in reducing contamination and illness 
related to ground beef. During 2004, 2,544 cases were reported through the NNDSS.  
The National E. coli Reference Laboratory at CDC provides serotyping and molecular 
characterization of virulence factors as a service to state public health laboratories. In 2004, 
CDC received 248 isolates of Shiga toxin-producing E. coli, non-O157. Isolates originated 
from 30 states and included 30 different O groups. The four most common O groups were O26 
(19%), O45 (13%), O111 (13%), and O103 (18%). A total of 308 cases of Shiga toxin-
producing E. coli non-O157 were reported to the NNDSS. 
Hemolytic Uremic Syndrome (HUS), Post-Diarrheal 
HUS is defined by the triad of hemolytic anemia, thrombocytopenia, and renal insufficiency. 
Patients reported in national notifiable diseases surveillance include only those with antecedent 
diarrheal illness. The most common etiology in the United States is infection with a Shiga 
toxin-producing E. coli, principally E. coli O157:H7. About 8% of persons infected with E. coli 
O157:H7 develop HUS. Of the 200 cases of HUS reported in 2004, 73.5% were in children 
younger than age 10 years. 
Listeriosis 
Listeriosis became nationally notifiable in 2000. Surveillance is conducted in through NNDSS. 
During 2004, 49 states or territories reported at least one case, for a total of 753 cases. 
Salmonella Typhi (Typhoid Fever) 
Infection with Salmonella serotype Typhi leads to typhoid fever. The number of cases of 
typhoid fever (322 in the NNDSS) has been relatively small and constant, mostly associated 
with travel outside the United States. S. Typhi isolates are reported through the National 
Salmonellosis Surveillance System; 306 isolates were reported in 2004.  
Salmonella, Non-Typhi (Salmonellosis) 
A total of 35,355 non-Typhi Salmonella isolates were reported in 2004. The national rate was 
12.0 per 100,000 population. Similar to other years, Salmonella was isolated most frequently 
from children younger than age 5 years, accounting for 27% of isolates. About 10% of isolates 
came from persons in each of the second through fifth decades of life, with lower proportions 
from persons in later decades of life. Since 1995, specific control programs have succeeded in 
the dramatically reducing Salmonella serotype Enteritidis, which has been associated with the 
internal contamination of eggs. However, other serotypes, such as Mississippi, Newport, 
Paratyphi B var. L(+) tartrate+ (formerly Java), and Javiana, have increased in numbers since 
1994. Rates of antibiotic resistance among several serotypes have been increasing. For more 
information about trends in antibiotic resistance, see the following sections at the end of this 
report: Sources and Contacts for Bacterial Foodborne and Diarrheal Diseases, Publications by 
Foodborne and Diarrheal Diseases Branch, 2004, and CDC Internet Sites Relevant to the  
National Antimicrobial Resistance Monitoring System (NARMS).  
Shigella (Shigellosis) 
Shigella transmission occurs most commonly via the fecal-oral route. Most Shigella sonnei 
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infections are associated with crowding and poor personal hygiene. Day care centers have been 
implicated in many S. sonnei outbreaks. 
A total of 9,343 Shigella isolates were reported to PHLIS in 2004. This represents a 50% 
decrease compared with 1994 and a 41% decrease from 2003. The national rate was 3.2 per 
100,000 population. Similar to previous years, children younger than age 5 years accounted for 
30.2% of all Shigella isolates. Another 31.6% came from persons aged 5–19 years, and 28.8% 
from persons aged 20–59 years. 
Of the 9,343 isolates, 88% were subgrouped. The relative proportions of the four different 
subgroups remained constant, with S. sonnei accounting for the largest percentage of isolates 
(68.9%), followed by S. flexneri (17.2%), S. boydii (1.8%), and S. dysenteriae (0.4%). 
Cholera, Toxigenic Non-O1 and Non-O139 V. Cholerae, and Other Vibrios 
In 2004, eight cases of toxigenic V. cholerae were reported. Five patients had cholera and were 
infected with toxigenic V. cholera serogroup O1: one patient acquired the infection in Thailand, 
two in India, one in the Philippines, and one in Hawaii. Toxigenic V. cholerae O141 was 
isolated from three patients. One patient was a Georgia resident who consumed oysters traced 
to a Florida harvest site. The second patient was a Georgia resident who reported no exposure 
to seafood before illness. The third patient was an Alabama resident who consumed oysters that 
could not be traced back to their harvest site. 
Other Vibrio isolates (excluding toxigenic V. cholerae) were not nationally notifiable in 2004, 
and not all states report cases. States bordering the Gulf of Mexico have a reporting agreement 
with CDC; others do not, but are encouraged to report cases. In 2004, 501 other Vibrio isolates 
from 479 patients were reported to the Cholera and Other Vibrios Surveillance System. Of 
these 479 patients, 130 (27%) were from Gulf Coast states, 211 (44%) were from Pacific Coast 
states, 100 (21%) were from Atlantic Coast states (excluding Florida), and 38 (8%) were from 
inland states. Among patients for whom information was available, 173 (38%) of 460 were 
hospitalized, and 39 (9%) of 443 died. V. parahaemolyticus was isolated from 240 (51%) 
patients, and was the most frequently reported Vibrio species. V. vulnificus was isolated from 
92 (19%) patients; 88% were hospitalized and 39% died. 
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Expanded Surveillance Summaries for Selected Pathogens and 
Diseases, 2004 
The following bacterial foodborne and diarrheal diseases case surveillance summaries for 2004 
are derived from individual reports sent to state and territorial epidemiologists and public 
health laboratory directors. They are compiled here to provide more detailed text, tables, and 
figures. An expanded summary of E. coli O157 infections, typhoid fever, and hemolytic uremic 
syndrome surveillance (HUS) data is not included in this report; more comprehensive 
surveillance data concerning these are available in FoodNet reports at 
http://www.cdc.gov/foodnet/. Only a few select tables and figures, from the Salmonella Annual 
Summary, 2004, and the Shigella Annual Summary, 2004, are included here. These complete 
reports are available at http://www.cdc.gov/ncidod/dbmd/phlisdata. 
Botulism 
The botulism surveillance case definition is available at 
http://www.cdc.gov/EPO/DPHSI/casedef/botulism_current.htm. Botulism is a rare but serious 
paralytic illness caused by a neurotoxin produced by the bacterium Clostridium botulinum. 
There are three main forms of botulism. Foodborne botulism is caused by eating foods that 
contain the botulism toxin. Wound botulism is caused by toxin produced from a wound 
infected with Clostridium botulinum. Infant botulism is caused by consumption of spores of the 
Clostridium botulinum organism, which then grow in the intestine of infants and release toxin. 
All forms of botulism can be fatal. Because many people can eat a food contaminated with the 
botulism toxin, every case of botulism suspected to be foodborne is considered a public health 
emergency. 
EDEB staff members are available to consult with health departments and physicians 24 hours 
a day. CDC also maintains the only source of antitoxin used to treat botulism in the United 
States. The request for consultation and release of antitoxin by health departments and 
physicians is the basis of surveillance for most cases of foodborne and wound botulism. States 
report cases of infant botulism to EDEB on a yearly basis; therapeutic human antitoxin licensed 
for treatment of infant botulism is available from the California Department of Health Services. 
Suspected botulism cases should be reported immediately to local or state public health 
officials, who then should call the CDC Emergency Operations Center at (770) 488-7100; CDC 
will immediately connect callers with an on-call botulism consultant. For consultation on 
suspected infant botulism occurring in any state, the Infant Botulism Treatment and Prevention 
Program of the California Department of Health Services should be contacted at (510) 231-
7600. 
A total of 138 cases of botulinum intoxication were reported to CDC in 2004. Among the 14 
cases of foodborne intoxication, toxin type A accounted for 12 (86%) cases and toxin type E 
for 2 (14%) cases. The median age of patients was 41 years; no deaths were reported. There 
were two multicase outbreaks. One was caused by “pruno,” a bootleg prison-made alcoholic 
beverage, and the other was caused by home-canned mushrooms.  
There were 91 reported cases of infant botulism in 2004. Toxin type B accounted for 54 (59%) 
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cases, toxin type A for 36 (40%) cases, and toxin type F for one (1%) case. The median age of 
patients was 15 weeks; one death was reported. 
There were 28 reported cases of wound botulism in 2004. Toxin type A accounted for all but 2 
cases. All occurred in injecting drug users. The median age of patients was 48 years; no deaths 
were reported. 
There were 4 cases of treatment-related botulism in one common-source outbreak. All 4 
patients received cosmetic injections of high-dose, unlicensed botulinum toxin A product not 
intended for human use. The patients were 34, 40, 52, and 53 years old. 
There was 1 reported case of botulism of unknown source. Toxin type F was responsible for 
this case, and the patient was 26 years old. There were no reported cases of adult colonization 
botulism. 
Table 2-1. Summary of cases of botulism reported to the Botulism Surveillance System, 
2004 
Type  Cases Median age Sex Toxin type Comments 







8 (57%) male 12 (86%) type A 
2 (14%) type E 
2 multicase outbreaks 






54 (59%) type B 
1 (1%) type F 






24 (86%) male 
25 (89%) type A 









2 (50%) male 
1 (100%) male 
1 (3%) toxin type 
undetermined 
4 (100%) type A 
1 (100%) type F 




Table 2-2. Cases of botulism reported to the Botulism Surveillance System, by state and type, 2004 
State/District Foodborne Infant Wound Other Total 
Arkansas 1 1 

Arizona  1 1 

California 6 37 21 64 

District of Columbia 1 1 

Delaware  2 2 

Florida  1 4* 5 

Hawaii 1 1 

Iowa  1 1 

Idaho  1 1 

Kansas  1 1 

Kentucky 1 1 

Maryland  6 6 

Minnesota 1 1 

Montana 1 1 2 

Nebraska  1 1 

New Hampshire 1 1 

New Jersey 1 1 2 

Ohio 1 2 3 

Oregon 4 1 1 6 

Pennsylvania 15 15 

South Carolina 1 1 

Tennessee 1 1 

Texas 3 1 4 

Utah  2 2 

Virginia  4 4

Washington  2 5 1† 8 

West Virginia 2 2 

Totals 14 91 28 5 138 
* Treatment-related. 
† Unknown source. 
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Table 2-3. Cases of foodborne botulism reported to the Botulism Surveillance System, by 

















































California* 35 Male A “Pruno” No 
California* 20 Male A “Pruno” No 


































* Cases involved in multicase outbreak. 
† Toxin type derived from epidemiologically linked case. 
‡ Bootleg prison-made alcoholic beverage. 
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Table 2-4. Cases of infant botulism reported to the Botulism Surveillance System, by 
month (N = 91), 2004 
Month State Age (weeks) Sex Toxin type Death 
January California 14 Female B No 
 Colorado 15 Male B N 
 Pennsylvania 26 Male B N 
 Washington 27 Male A N 
 Pennsylvania 26 Male A N 
 California 21 Male A N 
Utah 20 Female A N 
West Virginia 8 Female B N 
February California 22 Male A N 
 California 14 Male B N 
 Pennsylvania 18 Female B N 
 Ohio 6 Female B N 
 Minnesota 20 Male B N 
 Virginia 4 Female B N 
Texas 9 Male A N 
 West Virginia 4 Male B N 
March California 52 Female B N 
 Maryland 5 Female B N 
 Pennsylvania 21 Female B N 
 California 28 Male A N 
 Pennsylvania 24 Male B N 
 California 4 Female A N 
 Montana 38 Male A N 
 Virginia 3 Female B N 
April Utah 18 Male A N 
 California 22 Male B N 
 Pennsylvania 23 Female B N 
 Virginia 14 Male B N 
May California 9 Female A N 
 California 4 Male B N 
 Pennsylvania 13 Female B N 
June California 6 Female A N 
 Kentucky 14 Female B N 
 Delaware 19 Female B N 
 California 4 Male B N 
 California 3 Male B N 
 Pennsylvania 3 Male B N 
 California 31 Male A N 
 Washington 6 Male B N 
 California 9 Male B N 
 Pennsylvania 1 Female B N 
 California 24 Male A N 
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 California 23 Male A N 
July Idaho 19 Male A N 
 California 4 Female B N 
 California 4 Female B N 
 Arizona 22 Male B N 
 Maryland 21 Male B N 
 Oregon 7 Male B Unknown 
August California 15 Female A N 
 South Carolina 15 Female A N 
Texas 24 Female A N 
 California 11 Male B N 
 Virginia 10 Female A N 
 New Jersey 10 Female B N 
 Maryland 18 Female B N 
 Pennsylvania 27 Female B N 
September California 16 Male A N 
 California 4 Male B N 
 Delaware 4 Female B N 
 Pennsylvania 6 Female B N 
 Iowa 2 Male F Yes*
 Pennsylvania 26 Female B N 
 New Hampshire 2 Male B N 
 Maryland 26 Male A N 
Tennessee 14 Female B N 
 Ohio 19 Female B N 
 Kansas 4 Male B N 
October California 3 Male B N 
 Maryland 22 Male B N 
 California 16 Female A N 
 California 22 Male A N 
 Nebraska 15 Female A N 
 California 5 Female A N 
 California 20 Male A N 
 Florida 18 Male A N 
November California 14 Female A N 
 California 3 Male A N 
Hawaii 13 Female B N 
Texas 15 Male A N 
 Pennsylvania 20 Male B N 
 Pennsylvania 27 Male B N 
 Maryland 13 Male B N 
 California 18 Male A N 
December California 29 Male A N 
 Pennsylvania 25 Male B N 
 California 20 Male A N 
 California 7 Female A N 
14
District of Columbia 25 Male B N 
 California 26 Male B N 
 California 32 Female A N 
* Patient died from complications arising from Clostridium difficile colitis. 
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Table 2-5. Cases of wound botulism reported to the Botulism Surveillance System by 
month (N = 28), 2004 
Month State Age Sex Toxin Type Exposure Death 
(years) 
March California 37 Male A IDU* No 
 California 54 Male A IDU No 
 California 55 Male B IDU No 
 Washington 51 Male A IDU No 
 Washington 52 Male A IDU No 
June California 33 Male A IDU No 
 California 34 Male A IDU No 
 California 27 Male A IDU No 
 California 54 Male Unknown† IDU No 
July California 53 Male A IDU No 
 California 53 Male A IDU No 
Texas 49 Male A IDU No 
August California 49 Male A IDU No 
 California 55 Male A IDU No 
 Washington 49 Female A IDU No 
September California 50 Male A IDU No 
October California 42 Male A IDU No 
 California 47 Female A IDU No 
 California 56 Male A IDU No 
 Washington 50 Male A IDU No 
November California 52 Male A IDU No 
 California 53 Male A IDU No 
 California 57 Male A IDU No 
 Washington 43 Male A IDU No 
December California 43 Male A IDU No 
 California 49 Female A IDU No 
 California 52 Male A IDU No 
 Oregon 50 Female B IDU No 
* Injecting drug user. 
†Serum quantity not sufficient for toxin typing. 
16 
Table 2-6. Cases of treatment-associated botulism reported to the Botulism 
Surveillance System (N = 4), 2004 * 
Month State Age (years) Sex Toxin Type Death 
November Florida 53 Female A No 
November Florida 52 Male A No 
November Florida 40 Male A No 
November Florida 34 Female A No 
* All were part of a single common-source outbreak. 
Table 2-7 Cases of botulism of unknown source reported to the Botulism Surveillance 
System (N = 1), 2004 
Month State Age (years) Sex Toxin Type Death 
April Washington 26 Male F No 
Shiga Toxin-Producing Escherichia coli, non-O157 
The surveillance case definition for Shiga toxin-producing Escherichia coli non-O157 is 
available at http://www.cdc.gov/EPO/DPHSI/casedef/escherichia_coli_current.htm. 
Shiga toxin-producing Escherichia coli (STEC) strains cause diarrhea and hemolytic uremic 
syndrome (HUS). The most common STEC that causes illness in the United States is E. coli 
O157:H7. Non-O157 STEC strains are also important pathogens; they have caused several U.S. 
outbreaks and, in some U.S. studies, they have been isolated from diarrheal stools as frequently 
as E. coli O157:H7.  
In June 2000, the Council of State and Territorial Epidemiologists (CSTE) passed a position 
statement recommending inclusion of E. coli O157 and non-O157 STEC that cause human 
illness as nationally notifiable. Reporting of non-O157 STEC has increased every year since 
implementation in 2001. STEC is indicated as enterohemorrhagic Escherichia coli (EHEC) in 
NNDSS for 2004. 
During 2004, 308 cases of non-O157 STEC were reported through NNDSS. To better 
understand the non-O157 STEC serogroups associated with human illness, CDC encourages 
state health laboratories to forward suspected non-O157 STEC isolates to the CDC’s National 
Escherichia coli Reference Laboratory, where confirmatory testing for Shiga toxin genes and 
serotyping are offered. In 2004, 248 isolates were received by CDC from 30 states (Figure 3-1). 
The non-O157 isolates received by CDC in 2004 included 30 different O groups. The 
predominant groups were O26 (19%) and O103 (18%), followed by O45 (13%), O111 (13%), 
O145 (6%), and O121 (7%); these six O groups made up 76% of all isolates (Table 3-1). E. coli 
O26 was also the most commonly isolated non-O157 STEC in 2003 and 2002. In 2001, E. coli 
O111 was the most common.  
Identification of an STEC requires demonstrating the ability of the E. coli isolate to produce 
17 
Shiga toxin. Before 1995, Shiga toxin was detected by using highly technical assays available 
only at reference and research laboratories. Since 1995, the U.S. Food and Drug Administration 
(FDA) has licensed several rapid enzyme immunoassays (EIA) for the detection of Shiga toxin 
in human stool specimens and culture broth. Since these EIA kits have become commercially 
available and the use of polymerase chain reaction (PCR) to identity toxin genes has increased, 
the number of non-O157 STEC isolates sent to CDC for serotyping has increased each year. 
Health care providers evaluating patients with diarrhea or HUS should consider infection with 
non-O157 STEC in addition to E. coli O157. A small number of persons have developed HUS 
after urinary tract infection with STEC strains; in these cases, urine culture has yielded the 
pathogen when stool culture was negative. 
Health care providers should notify clinical diagnostic laboratories when STEC O157 infection 
is suspected so that appropriate testing methods can be applied. Clinical laboratories should 
strongly consider including STEC O157 in their routine bacterial enteric panel (with 
Salmonella, Shigella, and Campylobacter). The best way to identify all STEC infections is to 
screen all stool samples submitted for routine enteric bacterial testing for Shiga toxins using 
EIA or PCR. Ideally, the clinical diagnostic laboratory should culture simultaneously for STEC 
O157 (e.g., on a sorbitol-containing medium such as sorbitol MacConkey agar). Clinical 
diagnostic laboratories that use a Shiga toxin EIA, but do not perform simultaneous culture for 
STEC O157 should culture all Shiga toxin-positive broths for STEC O157 as soon as possible 
and forward these isolates to a state of local public health laboratory for confirmation and 
subtyping. When a Shiga toxin-positive broth does not yield STEC O157, then broth culture 
should be forwarded to the state of local public health laboratory for identification of non-O157 
STEC. State and local public health laboratories should confirm the presence of Shiga toxin in 
broths and should attempt to obtain a STEC isolate. All non-O157 STEC isolates should be sent 
by public health laboratories to CDC for confirmation and further characterization.  
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Table 3-1. Serogroup of non-O157 STEC isolates from humans sent to CDC, 2004 
Serogroup Number Percent 
O26 47 19.0% 

O103 44 17.7% 

O45 33 13.3% 

O111 32 12.9% 

O121 18 7.3% 

O145 14 5.6% 

O174 4 1.6% 

O118 3 1.2% 

O22 3 1.2% 

O112 2 0.8% 

O132 2 0.8% 

O158 2 0.8% 

O33 2 0.8% 

O76 2 0.8% 

O19 1 0.4% 

O27 1 0.4% 

O49 1 0.4% 

O63 1 0.4% 

O75 1 0.4% 

O77 1 0.4% 

O84 1 0.4% 

O86 1 0.4% 

O88 1 0.4% 

O91 1 0.4% 

O110 1 0.4% 

O126 1 0.4% 

O130 1 0.4% 

O131 1 0.4% 

O153 1 0.4% 

O165 1 0.4% 

Rough 10 4.0% 

Undetermined 14 5.6% 

Total 248 100.0% 
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* Data obtained from the National Escherichia coli reference Laboratory and the Epidemic 

Investigation and Surveillance Laboratory. 





The listeriosis surveillance case definition is available at 
http://www.cdc.gov/EPO/DPHSI/casedef/listeriosis_current.htm. Infection with Listeria 
monocytogenes is characterized by fever and muscle aches, and sometimes nausea or diarrhea. 
The nervous system can be affected, resulting in meningitis or cerebritis, with symptoms such as 
headache, stiff neck, confusion, or convulsions. Pregnant women, newborns, and adults with 
weakened immune systems are at greatest risk of developing listeriosis. Infection during 
pregnancy may be asymptomatic, but can result in miscarriage, premature delivery, or infection 
of the newborn. 
Listeriosis has been a nationally reportable disease since 2000. Reports of listeriosis are 
submitted to CDC through NNDSS. There were 753 cases of listeriosis reported to NNDSS 
during 2004 (0.3 cases per 100,000 population). The rate of listeriosis was highest among 
neonates (1.5 cases per 100,000), followed by adults older than age 70 years (1.1 cases per 
100,000). More comprehensive surveillance data on listeriosis incidence rates are available in 
FoodNet reports at http://www.cdc.gov/foodnet/. 
The Listeriosis Initiative is an effort to aid in investigations of future Listeria outbreaks and 
clusters. Timely isolation and subtyping of all isolates of L. monocytogenes and prompt 
interviews of patients are means to improving outbreak investigation. During 2004, FoodNet 
sites piloted the use of a standard interview form for cases of infection with Listeria. Data from 
the standard, detailed report form are maintained in a central database for rapid analysis in the 
event of an outbreak. These data can be used for case-control analysis of a cluster, where people 
with non-matching isolates serve as controls. Prompt data collection and analysis could allow 
earlier public health intervention during an outbreak.  
All isolates of Listeria should be submitted for subtyping to state or national laboratories. Public 
health professionals and health care providers should consider interviewing all cases of listeriosis 




The Salmonella surveillance case definition is available at 
http://www.cdc.gov/epo/dphsi/casedef/salmonellosis_current.htm. The National Salmonella 
Surveillance System collects reports of isolates of Salmonella from human sources from every 
state. Salmonella isolates are submitted to the state public health laboratory by clinical 
diagnostic laboratories. The state and territorial laboratories confirm the isolates as Salmonella, 
perform serotyping according to the Kauffmann-White scheme, and report the data 
electronically through PHLIS to EDEB. Unusual or difficult isolates are forward to the 
National Salmonella Reference Laboratory at CDC for further characterization or confirmation. 
These results are reported back to the state laboratory, where they are reported through PHLIS. 
Duplicates are removed from the file at the end of the year. Every 20th isolate is forwarded to 
the National Antimicrobial Resistance Monitoring System (NARMS) at CDC for susceptibility 
testing. 
The capture of isolates in the National Salmonella Surveillance System is considered to be 
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fairly complete. However, some Salmonella isolates may not be forwarded to public health 
laboratories, and therefore are not reported. In addition, irrespective of the surveillance system, 
many cases of Salmonella illness are not reported because the ill person does not seek medical 
care, the health care provider does not obtain a specimen for diagnosis, or the laboratory does 
not perform the necessary diagnostics tests. The results of surveillance reported here should be 
considered underestimates of the true number of infections. 
The reporting state represents the state where laboratory confirmation and serotyping were 
performed. In some instances, the reporting state is not the state of residence of the person from 
whom the isolate was obtained. For Salmonella serotype Typhi, only the first isolation in one 
year for each person is counted. 
A total of 35,661 Salmonella isolates were reported from public health laboratories in 49 states 
and the District of Columbia in 2004. This represents a 5% increase compared with 1994 and a 
5% decrease from 2003. The national rate was 12.1 per 100,000 population.  
Similar to other years, Salmonella was isolated most frequently from children younger than age 
5 years, accounting for 27% of isolates. About 10% of isolates came from persons in each of 
the second through fifth decades of life, with lower proportions from persons in later decades of 
life. The distribution of isolates between the sexes was different, with a greater proportion of 
isolates from male than female infants and children, and a smaller proportion of isolates from 
male than female adults. 
The 20 most common serotypes of Salmonella in 2004 are listed in Table 4-1. These represent 
75% of all Salmonella isolates. Of the top 20 serotypes, the two most common serotypes, S. 
Typhimurium and S. Enteritidis, had substantial decreases in number during 1994–2004; the 
largest percent decrease in numbers compared with 1994 were in serotypes Hadar and 
Enteritidis. A dramatic increase in serotype Mississippi (up 267% from 1994 to 2004) mainly 
occurred before 1999. Serotypes Javiana, Paratyphi B var. L(+) tartrate+ (formerly serotype 
Java), and Newport had important increases in numbers since 1994 (up 228%, 106%, and 99%, 
respectively). In 2004, serotypes Berta and Anatum increased in rank to be included in the top 
20 serotypes, whereas serotypes Bareilly and Stanley dropped from the top 20 serotypes 
compared with 2003.  
Salmonella serotype I 4,[5],12:i:- was introduced as the 18th most common serotype in 2002 
and has increased in rank to seventh in 2004. This serotype was first tracked in the National 
Salmonella Surveillance System database in 1998, though many isolates may have been 
classified as only Subspecies I or Group B before then. Since the 2003 Salmonella Surveillance 
Summary was published, we reexamined the surveillance data for 1995–2003 and were able to 
reclassify some isolates submitted in these years as I 4,[5],12:i:- on the basis of additional data 
submitted with individual isolates. Efforts to correctly classify this serotype are responsible for 
at least some of the increase that has been documented in recent years. It is unknown how many 
isolates reported as Subspecies I, Group B could be this serotype. In 1998, this serotype was the 
fourth most commonly identified in Spain; genetic analysis of the Spanish isolates revealed a 
close relationship to serotype Typhimurium. Many U.S. isolates of this serotype were 
characterized by pulsed-field gel electrophoresis (PFGE), and their patterns were submitted to 
PulseNet, the National Molecular Subtyping Network for Foodborne Disease Surveillance. The 
PFGE patterns for most I 4,[5],12:i:- isolates were closely related to the PFGE patterns for 
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serotype Typhimurium, indicating that they are most likely variants of Typhimurium. 
The three most common serotypes of Salmonella in 2004 (Typhimurium, Enteritidis, and 
Newport) accounted for 43% of isolates. During the past 10 years, S. Typhimurium and S. 
Enteritidis were ranked first and second, respectively; during 1994–1996, their ranks were 
temporarily reversed (Figure 4-1). A large proportion of S. Typhimurium isolates are resistant 
to multiple antimicrobial drugs. In a 2003 national survey, 45% were resistant to one or more 
drugs and 26% had a five-drug resistance pattern characteristic of a single phage type, DT104 
(see http://www.cdc.gov/narms/). Similarly, serotype Newport has emerged as a major 
multidrug-resistant pathogen. In 2003, 46 (21%) of 222 Newport isolates submitted to NARMS 
were resistant to at least seven of 17 antimicrobial agents tested, including extended spectrum 
cephalosporins. Similar to other years, there were marked regional differences in the frequency 
of Salmonella isolates among serotypes. The rate of isolations by region has been followed 
closely for serotype Enteritidis as a means of assessing the impact of egg safety regulations and 
industry improvements. As indicated in Figure 4-2, rates of isolation had been relatively high in 
the New England, Mid-Atlantic, and Pacific regions, but have shown significant decreases 
since 1995. Although New England had an increase in serotype Enteritidis in 2000 and 2001 
compared with 1999, the rate has decreased since 2001. 
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Table 4-1. The 20 Salmonella serotypes most frequently reported to PHLIS, 2004 
Rank Serotype Number Percent 
1 Typhimurium* 6,842 19.2% 
2 Enteritidis 5,012 14.1% 
3 Newport 3,325 9.3% 
4 Javiana 1,772 5.0% 
5 Heidelberg 1,757 4.0% 
6 Montevideo 870 2.4% 
7 I 4,[5],12:i:- 739 2.1% 
8 Muenchen 739 2.1% 
9 Saintpaul 692 1.9% 
10 Braenderup 684 1.9% 
11 Infantis 588 1.6% 
12 Mississippi 558 1.6% 
13 Oranienburg 495 1.4% 
14 Thompson 493 1.4% 
15 Berta 409 1.1% 
16 Agona 406 1.1% 
17 Paratyphi B var. L(+) 354 1.0% 
tartrate+ 
18 Typhi 306 0.9% 
19 Hadar 277 0.7% 
20 Anatum 250 0.7% 
Subtotal 26,568 74.5% 
All other serotypes 5,651 15.8% 
Unknown 2,053 5.8% 
Partially serotyped isolates 1,328 3.7% 
Rough or nonmotile isolates 61 0.2% 
Subtotal 9,093 25.5% 
Total 35,661 100.0% 
* Typhimurium includes var. Copenhagen. 
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Figure 4-1. Isolation rate per 100,000 population for the top four serotypes of 
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Figure 4-2. Isolation rate per 100,000 population for Salmonella Enteritidis reported to 
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Shigella 
The Shigella surveillance case definition is available at 
http://www.cdc.gov/epo/dphsi/casedef/shigellosis_current.htm. The National Shigella 
Surveillance System collects reports of isolates of Shigella from every state. Shigella isolates 
are submitted to the state public health laboratory by clinical diagnostic laboratories. The state 
and territorial laboratories confirm the isolates as Shigella, perform subtyping, and report the 
data electronically through PHLIS to EDEB. Unusual or untypable isolates are forwarded to the 
National Shigella Reference Laboratory at CDC for further characterization or confirmation. 
These results are reported back to the state laboratory, where they are reported to CDC through 
PHLIS. Duplicates are removed from the file at the end of the year.  
The capture of isolates in the National Shigella Surveillance System is considered to be 
consistent. However, some Shigella isolates may not be forwarded or reported to state public 
health laboratories, and therefore are not captured. In addition, irrespective of the surveillance 
system, many cases of Shigella illness are not reported because the ill person does not seek 
medical care, the health care provider does not obtain a specimen for diagnosis, or the 
laboratory does not perform culture for Shigella. The results of surveillance reported here are 
therefore substantial underestimates of the true number of infections. 
The reporting state represents the state where laboratory confirmation and subtyping were 
performed. In some instances, the reporting state is not the same as the state of residence of the 
person from whom the isolate was obtained.  
There are four major subgroups and 44 recognized serotypes of Shigella that are differentiated 
from one another by their biochemical traits (such as ability to ferment mannitol) and antigenic 
properties (Table 5-1). 
A total of 9,343 Shigella isolates were reported from public health laboratories in 50 states in 
2004 (Table 5-2). This represents a 50% decrease compared with 1994 and a 41% increase from 
2003. The national rate was 3.2 per 100,000 population. 
Similar to previous years, children younger than age 5 years accounted for 30.2% of all Shigella 
isolates. About 31.6% came from persons aged 5–19 years, and 28.8 % from persons aged 20– 
59, with declining numbers thereafter. The overall distribution of Shigella isolates between the 
sexes was similar, with females accounting for 48.4% of persons from whom Shigella was 
isolated. The frequency of reported subgroups and the frequency of reported serotypes within 
these groups for all Shigella isolates are shown in Tables 5-2 and 5-3. Of the 9,343 isolates, 
8,242 (88.2%) were subgrouped. The relative proportions of the four different subgroups 
remained constant, with S. sonnei accounting for the largest percentage of isolates (68.9%), 
followed by S. flexneri (17.2%), S. boydii, (1.8%), and S. dysenteriae (0.4%). Over the past 
decade, the numbers of reported Shigella isolates in subgroups S. flexneri, S. boydii, and S. 
dysenteriae and the proportions of all reported Shigella isolates caused by these three subgroups 
have declined. Slight increases in the number of S. boydii isolates were observed in both 2003 
and 2004. The number (1,101) and the proportion (11.8%) of all reported Shigella isolates that 
were not identified as belonging to a specific subgroup also increased.  
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Table 5-1. Classification of Shigella subgroups 
Subgroup Subgroup Serotypes Fermentation of Subgroup B Group 
D-Mannitol Antigens 
A S. dysenteriae 15 - -
B S. flexneri 8* + + 
C S. boydii 20 + -
D S. sonnei 1 + -
* Serotypes 1–5 are subdivided into 11 subserotypes. 
Table 5-2. Shigella subgroups reported to PHLIS, 2004 
Rank Subgroup Number Percent 
1 S sonnei 6,433 68.9 
2 S. flexneri 1,603 17.2 
3 S. boydii 169 1.6 
4 S. dysenteriae 37 0.4 
Subtotal 8,242 88.2 
Unknown 1,101 11.8 
Total 9,343 100.0 
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Table 5-3. Rank and number of isolates of Shigella serotypes reported to PHLIS, 2004 
Rank Serotype Number Percent 
1 S. sonnei 6433 68.9% 
2 S. flexneri unspecified 814 8.7% 
3 S. flexneri 2 unspecified 185 2.0% 
4 S. flexneri 3 unspecified 112 1.2% 
5 S. boydii unspecified  111 1.2% 
6 S. flexneri 1 unspecified  98 1.2% 
7 S. flexneri 2a  89 1.0% 
8 S. flexneri 4 unspecified  69 0.7% 
9 S. flexneri 3a  53 0.6% 
10 S. flexneri 4a  53 0.6% 
11 S. flexneri 6 42 0.5% 
12 S. flexneri 1b 27 0.3% 
13 S. flexneri variant y  26 0.3% 
14 S. dysenteriae unspecified 22 0.2% 
15 S. boydii 2 20 0.2% 
16 S. boydii 4 15 0.2% 
17 S. flexneri 3b 13 0.1% 
18 S. boydii 1 10 0.1% 
19 S. flexneri 2b  10 0.1% 
20 S. flexneri variant x  5 0.1% 
21 S. dysenteriae 1  4 0.0% 
22 S. dysenteriae 2 4 0.0% 
23 S. dysenteriae 3 4 0.0% 
24 S. boydii 10 3 0.0% 
25 S. boydii 14 3 0.0% 
26 S. boydii 5 3 0.0% 
27 S. flexneri 5 unspecified  3 0.0% 
28 S. boydii 8 2 0.0% 
29 S. dysenteriae 12 2 0.0% 
30 S. flexneri 5a  2 0.0% 
31 S. boydii 12 1 0.0% 
32 S. boydii 20 1 0.0% 
33 S. dysenteriae 4 1 0.0% 
34 S. flexneri 1a  1 0.0% 
35 S. flexneri 88-893 1 0.0% 
Subtotal 8,242 88.2% 
Unknown 1,101 11.8% 
Total 9,343 100.0% 
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Vibrio 
The cholera and vibriosis (non-cholera Vibrio species) surveillance case definitions are available 
at http://www.cdc.gov/epo/dphsi/casedef/cholera_current.htm and 
http://www.cdc.gov/epo/dphsi/casedef/vibriosis.htm. Infection with toxigenic Vibrio cholerae 
O1 and O139, the causative agents of cholera, has been a reportable disease in the United States 
for many years. More recently, toxigenic V. cholerae O141 has emerged as a cause of illness, 
but it does not cause cholera and is not notifiable. 
The Cholera and Other Vibrio Illness Surveillance System (COVIS) was initiated by CDC, FDA, 
and the Gulf Coast states (Alabama, Florida, Louisiana, Mississippi, and Texas) in 1988. CDC 
has maintained a database of reported Vibrio infections from humans in order to obtain reliable 
information on illnesses associated with Vibrio species. Participating health officials collect 
clinical data, information about underlying illness, history of seafood consumption, and exposure 
to seawater in the 7 days before illness, and then conduct tracebacks of implicated oysters. This 
information has been used to educate consumers about the health risks of seafood, as well as to 
help determine host, food, and environmental risk factors. Since 1997, many other states have 
also reported Vibrio isolates. However, only toxigenic V. cholerae O1 and O139, the causative 
agents of cholera, were nationally notifiable during 2005; thus the true number of Vibrio isolates 
is greater than reported. CDC serotypes all V. parahaemolyticus isolates received from state 
health departments and screens for cholera toxin production in all V. cholerae isolates. 
Results are summarized using CDC form 52.79, Cholera and Other Vibrio Illnesses Surveillance 
Report and presented in two categories: V. cholerae isolates that produce cholera toxin (referred 
to as toxigenic V. cholerae) and all other Vibrio isolates (including those V. cholerae isolates that 
do not produce cholera toxin). Results are presented separately for Gulf Coast states versus other 
states to be consistent with previous reports. Additionally, results are presented by anatomic site 
of isolation. It is important to note that isolation of some Vibrio species from a patient with illness 
does not necessarily indicate causation. While many Vibrio species are well-recognized 
pathogens, the status of V. damsela, V. furnissii, V. metschnikovii, and V. cincinnatiensis as 
enteric pathogens is less clear. 
Isolates of toxigenic Vibrio cholerae 
In 2004, eight patients with toxigenic V. cholerae were reported (Table 6-1). Five patients had 
cholera and were infected with toxigenic V. cholerae serogroup O1. One patient acquired the 
infection in Thailand, two while traveling in India, one in the Philippines, and one in Hawaii. The 
two patients who acquired infection during travel in India were unrelated cases, and they traveled 
to India 4 months apart from each other. Three patients were hospitalized and one died. No 
isolates of toxigenic V. cholerae O139 were identified. Toxigenic V. cholerae O141 was isolated 
from three patients. One patient was a male Georgia resident who consumed oysters 3 days before 
onset of his symptoms. The oysters were traced to a harvest site in Florida. The second patient 
was a female Georgia resident who reported no exposure to seafood in the 10 days preceding 
illness. The third patient was a male Alabama resident who consumed oysters 10 days before 
onset of his symptoms. The oysters could not be traced back to their harvest site.  
Other Vibrio isolates (excluding toxigenic V. cholerae) 

In 2004, 501 Vibrio isolates (excluding toxigenic V. cholerae) from 479 patients were reported to 
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COVIS. Among patients for whom information was available, 173 (38%) of 460 were 
hospitalized and 39 (9%) of 443 died. V. parahaemolyticus was isolated from 240 (51%) patients, 
and was the most frequently reported Vibrio species. Of the patients infected with V. 
parahaemolyticus, 20% were hospitalized and 1% died. V. vulnificus was isolated from 92 (19%) 
patients; 88% were hospitalized and 39% died. The following sections provide further 
information on these non-toxigenic Vibrio isolates: 
Geographic location: In 2004, we received 130 (27%) reports of Vibrio illness from Gulf Coast 
states, 211 (44%) from Pacific Coast states, 100 (21%) from Atlantic Coast states (excluding 
Florida), and 38 (8%) from inland states (Figure 6-1). The most frequent Vibrio species reported 
from Gulf Coast states were V. vulnificus (47%), V. parahaemolyticus (21%), and non-toxigenic 
V. cholerae (9%). The most frequent Vibrio species reported from non-Gulf Coast states were V. 
parahaemolyticus (61%), V. alginolyticus (11%), V. vulnificus (9%), and non-toxigenic V. 
cholerae (7%). 
Anatomic site of isolation: Among the 501 Vibrio isolates, 265 (53%) were from stool, 87 
(17%) from blood, and 72 (14%) from wounds. In addition, 23 (5%) isolates were obtained 
from the ear, and 20 (4%) were from the gallbladder, urine, or other site. V. parahaemolyticus 
was the species most frequently isolated from stool (199 [75%] of 265 isolates from stool); V. 
vulnificus was the species most frequently isolated from blood (64 [74%] of 87 isolates from 
blood) and from wounds (28 [39%] of 72 isolates from wounds).  
Seasonality: The number of patients from whom Vibrio species was isolated had a clear seasonal 
peak during the summer months (Figure 6-2). The greatest frequency occurred in July for Gulf 
Coast states and in August for non-Gulf Coast states. 
Exposures: Among the 479 patients, 114 (24%) patients reported having a wound either before or 
during exposure to Vibrio. Of those, 43 (38%) reported water activities such as swimming and 
boating, 19 (17%) reported handling seafood, and 18 (16%) reported contact with marine wildlife. 
Excluding patients from whom Vibrio was isolated from a wound, and among the 255 for whom a 
food history was available, 223 (87%) reported eating seafood in the 7 days before illness onset. 
Among the 118 who reported eating a single seafood item (Table 6-4), 69% ate oysters (88% of 
whom consumed them raw), 10% ate shrimp, and 7% ate finfish. International travel in the 7 days 
before illness onset was reported by 11 (12%) of patients.  
Laboratory: For reports where laboratory confirmation was available, the state public health 
laboratory confirmed the identification of 165 (95%) of 173 human Vibrio isolates. CDC received 
81 isolates of V. parahaemolyticus from 80 patients. Of these, 76 were viable, four were not 
viable, and one was not Vibrio. Of the viable V. parahaemolyticus isolates, 14 (17%) from eight 
states were serotype O4:K12 (Illinois, Indiana, Louisiana, Massachusetts, Montana, Nevada, New 
York, and Oregon), 12 (15%) isolates from 10 states were serotype O3:K6 (Arizona, Colorado, 
Connecticut, Georgia, Hawaii, Illinois, Louisiana, New Hampshire, Texas, and Utah), 10 (12%) 
isolates from four states were serotype O6:K18 (Alaska, Nevada, Oregon, and Washington), and 
the remaining 40 isolates were one of 20 serotypes.  
Outbreaks: One outbreak of V. parahaemolyticus serotype O6:K18 in which 62 persons were ill 
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(10 culture-confirmed) from consumption of raw oysters harvested from Alaskan waters was 
reported from Alaska. Individual case reports from this outbreak were not submitted to COVIS 
and are not included in this summary. 
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Table 6-1. Isolates of toxigenic V. cholerae reported to COVIS, 2004 
State Age Sex Onset Suspected Exposure Serogroup Serotype 
Hawaii 44 Female 1/9/2004 Exposure in the Philippines V. cholerae O1 Ogawa 
Illinois 65 Male 2/10/2004 Exposure to raw seafood in Thailand V. cholerae O1 Inaba 
California 48 Female 4/7/2004 Exposure in India V. cholerae O1 Inaba 
Hawaii 60 Female 5/16/2004 Exposure to raw, imported seafood V. cholerae O1 Ogawa 
Georgia 50 Male 7/27/2004 Exposure to oysters in Georgia V. cholerae O141 Unknown 
Georgia 58 Female 7/28/2004 Unknown V. cholerae O141 Unknown 
Alabama 63 Male 10/18/2004 Exposure to oysters in Florida V. cholerae O141 Unknown 
New York 51 Male 12/16/2004 Exposure in India V. cholerae O1 Inaba 
Table 6-2. Number of Vibrio isolates (excluding toxigenic V. cholerae) reported to COVIS, 
by species, complications, and site of isolation in patients from Gulf Coast states, 2004  
Complications* Site of Isolation 
Vibrio Species Patients Hospitalized Deaths Isolates Stool Blood Wound Other† 
N (%) n/N (%) n/N (%) N (%) 
V. alginolyticus 7 (5) 3/6 (50) 0/6 (0) 7 (4) 0 0 4 3 
V. cholerae 
(non-toxigenic)‡ 12 (9) 6/11 (55) 1/11 (9) 13 (9) 6 6 1 0 
V. damsela 1 (1) 1/1 (100) 0/1 (0) 1 (1) 0 0 1 0 
V. fluvialis 7 (5) 3/7 (43) 0/7 (0) 7 (5) 5 0 1 1 
V. hollisae 1 (1) 0/1 (0) 0/1 (0) 1 (1) 1 0 0 0 
V. mimicus 5 (4) 2/5 (40) 0/5 (0) 5 (4) 5 0 0 0 
V. parahaemolyticus 27 (21) 13/26 (50) 1/24 (4) 28 (20) 19 1 6 2 
V. vulnificus 60 (47) 52/59 (88) 19/53 (36) 66 (47) 1 40 20 5 
Other 2 (2) 1/2 (50) 0/1 (0) 2 (1) 0 0 1 1 
Species not 
identified 7 (5) 2/5 (40) 1/6 (17) 7 (5) 2 1 2 2 
Multiple species§ 1 (1) 1/1 (100) 0/2 (0) 4 (3) 0 2 2 0 
Total 130 (100) 84/124 (68) 22/117 (19) 141 (100) 39 50 36 16 
* Denominators indicate patients for whom information is known. 
† Includes ear, eye, gall bladder, peritoneal fluid, sputum, leg tissue, and unknown source. 
‡ Non-toxigenic V. cholerae. Includes non-toxigenic V. cholerae O1 (1 isolate) and other non-toxigenic 
V. cholerae (non-O1 non-O139) (11 isolates). 
§ V. parahaemolyticus and V. vulnificus were isolated from the wound and blood of one patient. 
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Table 6-3. Number of Vibrio isolates (excluding toxigenic V. cholerae) reported to COVIS, 
by species, complications, and site of isolation in patients from non-Gulf Coast states, 2004  
Complications* Site of Isolation 
Vibrio Species Patients Hospitalized Deaths Isolates Stool Blood Wound Other† 
N (%) n/N (%) n/N (%) N (%) 
V. alginolyticus 37 (11) 7/35 (20) 1/33 (3) 37 (10) 2 2 17 16 
V. cholerae 
(non-toxigenic)‡ 28 (7) 6/27 (22) 0/27 (0) 28 (8) 19 3 1 5 
V. damsela 2 (1) 2/2 (100) 0/2 (0) 2 (1) 0 0 1 1 
V. fluvialis 10 (3) 4/9 (44) 0/10 (0) 10 (3) 6 1 1 2 
V. furnissii 2 (1) 1/2 (50) 0/2 (0) 2 (1) 1 0 1 0 
V. hollisae 1 (0) 1/1 (100) 0/1 (0) 1 (0) 1 0 0 0 
V. mimicus 4 (1) 0/4 (0) 0/4 (0) 4 (1) 3 0 0 1 
V. parahaemolyticus 213 (61) 33/204 (16) 2/197 (1) 215 (60) 180 4 6 25 
V. vulnificus 32 (9) 28/32 (88) 13/30 (43) 37 (10) 4 24 8 1 
Other 1 (0) 0/1 (0) 0/1 (0) 1 (0) 1 0 0 0 
Species not identified 15 (4) 5/15 (33) 0/15 (0) 15 (4) 5 1 1 8 
Multiple species§ 4 (1) 2/4 (50) 1/4 (25) 8 (2) 4 2 2 0 
Total 349 (100) 89/336 (26) 17/326 (5) 360 (100) 226 37 36 61 
* Denominators indicate patients for whom information is known. 
† Includes ear, urine, sputum, foot tissue, thigh tissue, endotracheal intubation, incision, and unknown source. 
† Non-toxigenic V. cholerae. Includes non-toxigenic V. cholerae O1 (2 isolates) and other non-toxigenic V. cholerae 
(non-O1 non-O139) (26 isolates).
§ V. cholerae non-01, non-0139 and V. parahaemolyticus were isolated from the stool of one patient; V. damsela and 
V. vulnificus were isolated from the thigh wound of a second patient; V. cholerae non-01, non-0139 and V. mimicus 




Table 6-4. Seafood exposure among patients with foodborne Vibrio infection (excluding toxigenic V. cholerae) who reported eating a 
single seafood item in the week before illness onset, 2004 
Mollusks Crustaceans Other Finfish† Total 
Shellfish* 
Oysters Clams Mussels Shrimp Lobster Crab Crayfish 
Ate (%) 81 (69) 3 (3) 0 (0) 12 (10) 0 (0) 6 (5) 2 (2) 6 (5) 8 (7) 118 
Ate raw (%) 88 67 0 8 0 33 0 33 50 82 
* Other shellfish reported: calamari, squid, and scallops. 
† Finfish reported: salmon, trout, catfish, tilapia, sushi, tuna, and eel. 
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Figure 6-1. Number of patients with Vibrio isolates (excluding toxigenic V. cholerae) 






























* 62 cases of Vibrio parahaemolyticus from an outbreak during summer 2004 
Figure 6-2. Number of patients with Vibrio isolates (excluding toxigenic V. cholerae) 
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*Onset date missing or unknown for 4 patients 
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Data Sources and Background 
CDC conducts national surveillance to define the magnitude and burden of diseases, to identify 
outbreaks or high-risk groups so that preventive actions can be taken, and to track the 
effectiveness of control and prevention measures. The surveillance systems for different 
foodborne pathogens have evolved over time. There are many distinct surveillance systems, 
some managed by individual program areas (e.g., botulism surveillance), and others 
administered and used more broadly. 
National Notifiable Diseases Surveillance System (NNDSS)and National Electronic 
Telecommunications System for Surveillance (NETSS) 
The origins of NNDSS date back to 1878 when Congress authorized the U.S. Marine Hospital 
Service to collect morbidity reports regarding cholera, smallpox, plague, and yellow fever from 
U.S. consuls oversees. Today, NNDSS is operated by CDC in collaboration with the Council of 
State and Territorial Epidemiologist (CSTE) and serves as a timely source of national disease 
data. NETSS is the software and electronic communication pathway by which NNDSS data 
reach the CDC; this whole system is often identified by the NETSS acronym. NETSS is 
administered by CDC’s National Center for Public Health Informatics (NCPHI).  
There are several sources of NETSS surveillance information for individual infections. For 
many diseases, public health authorities at state departments of health request or require that 
physicians and other health care workers report cases to the local health department. For some 
diseases, authorities also request or require clinical laboratories to report the identification or 
isolation of certain pathogens. These reports are summarized and forwarded to the state 
department of health, which then sends the information to CDC if the disease is nationally 
notifiable. 
Public Health Laboratory Information System (PHLIS) 
In addition to allowing public health authorities to track diagnosed cases of notifiable disease, 
sending pathogens isolated from patients to public health laboratories to confirm the identity of 
the organism and its subtype provides an additional public health benefit. This process can 
identify clusters of a specific subtypes and link events from widely dispersed locations. An 
example is surveillance for serotype of Salmonella. In 1962, CDC, CSTE, and the Association 
of State and Territorial Public Health Laboratory Directors agreed to serotype Salmonella 
isolates and send the resulting information to CDC weekly. Eight states participated initially. 
Eventually, all 50 states began transmitting information throuth PHLIS, an electronic network 
tool developed in the 1980s. PHLIS collects laboratory surveillance information for a large 
number of pathogens (foodborne and non-foodborne). In 2004, it was administered by the 
Biostatistics and Information Management Branch of the Division of Bacterial and Mycotic 
Diseases, located in CDC’s National Center for Infectious Diseases. PHLIS information has 
been used to identify, investigate, and control outbreaks of salmonellosis and other foodborne 
diseases at local, regional, national, and international levels. 
Limitations Common to NETSS and PHLIS 
Most surveillance systems for foodborne and diarrheal diseases tend to underestimate the 
burden of disease. Diseases that cause severe clinical illness are most likely to be reported 
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accurately if they were diagnosed by a physician. However, persons who have diseases that are 
clinically mild and infrequently associated with severe consequences might not seek medical 
care from a health care provider, and these diseases are never diagnosed. Even if these less 
severe diseases are diagnosed, they are less likely to be reported in surveillance systems. 
The information reported about each case is typically limited to age, sex, county of residence, 
date of diagnosis, and a small number of other variables. The degree of completeness of data 
reporting is also influenced by the diagnostic facilities available; the control measures in effect; 
the public awareness of a specific disease; and the interests, resources, and priorities of state 
and local officials responsible for disease control and public health surveillance. Factors such 
as changes in the case definitions for public health surveillance, the introduction of new 
diagnostic tests, or the discovery of new disease entities can cause changes in disease reporting 
that are independent of the true incidence of disease.  
Some important infections that are difficult to diagnose are not included in general surveillance. 
For example, the diagnosis of enterotoxigenic E. coli remains restricted to a few research and 
large public health laboratories, and tests for this pathogen are not performed in standard 
clinical laboratories. Surveillance systems cannot track infections by this cause of foodborne 
diarrheal illness. 
Limitations Specific to NETSS and PHLIS 
NETSS is a passive surveillance system that relies on a mix of clinicians and laboratories that 
vary by state and by pathogen to report cases or pathogen isolations. The system includes cases 
that are diagnosed only clinically (on the basis of symptoms, signs, and the epidemiological 
setting) as well as cases that are diagnosed by a definitive laboratory test. The willingness of 
clinicians to report cases varies from disease to disease, and the completeness and timeliness of 
reporting is problematic for some diseases. The data do not include the specific findings of the 
public health laboratory, such as a subtype, and therefore are not useful for detecting clusters of 
a particular subtype. The lack of subtyping for common pathogens makes detection of 
outbreaks difficult, especially those that are multi-jurisdictional. This is particularly true for 
Salmonella and Shigella infections. 
PHLIS, a public health laboratory-based surveillance system, is also limited as a passive 
system; it relies on clinical laboratories to send Salmonella and other isolates to the state public 
health laboratory for subtyping. For example, because there is no routine referral or subtyping 
of Campylobacter strains in the United States, state public health laboratories may report only 
those strains that they isolate themselves (e.g., from patients in public health clinics or from 
specimens collected in outbreak investigations). The number of Campylobacter isolates 
reported through PHLIS is typically a small fraction of the number diagnosed. The need to send 
an isolate from the original clinical laboratory to the state public health laboratory and the need 
for the state laboratory to do the serotyping means that reports may be delayed. Training and 
support are required to ensure that state laboratories have the specialized skills and reagents 
needed to perform serotyping or other subtyping methods. The PHLIS software, written first in 
the late 1980s, has not been fully integrated into other software used in the states, and its use 
requires training. 
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State-to-State Variations in Reported Cases 
There is substantial variation in the number of reported cases from one state compared to 
another, even when taking into account the differences in population sizes among states. One 
major source of variation is that a given disease may be reportable in one state but not in 
another, even for nationally notifiable diseases. Reporting requirements are under state 
jurisdiction. There may also be substantial variation from one state to another depending on 
local resources, interests, and priorities. When more than one route is available for reporting 
surveillance data within the public health system, states may choose to use one or the other or 
more than one. For example, some state public health laboratories report E. coli O157:H7 
isolates that they receive for confirmation through PHLIS, and some state epidemiology offices 
report infections with this organism through NETSS.  
Some states may chose to submit reports on diseases for which they have collected information, 
but which are not nationally notifiable. These data indicate the interest and concern with that 
disease within that specific state. 
In addition, there are substantial state-to-state and regional differences in the incidence of 
certain diseases. For example, PHLIS has demonstrated that some Salmonella serotypes are 
isolated with similar frequency in persons in all U.S. regions, while other serotypes are highly 
localized. The PHLIS Salmonella Surveillance System is a stable system that has been 
functioning well for several decades with full national participation, so these results are 
considered valid. 
Program-Specific Surveillance Systems 
Because both NETSS and PHLIS collect little information beyond very basic patient 
demographics (e.g., age, sex, race, place, time) and pathogen characteristics, EDEB collects 
more detailed information on individual cases for some diseases because this information is 
needed for accurate monitoring and effective intervention. These include botulism, typhoid 
fever, and cholera and Vibrio species infections. For botulism, typhoid fever, and cholera, 
reporting is nationwide. For the noncholera Vibrio species, reporting is mainly through a 
surveillance alliance with the Gulf Coast states of Alabama, Florida, Louisiana, and Texas. 
Vibrio surveillance also includes voluntary reporting from many other states. These systems 
and their resulting databases are distinct and separate from each other and from NETSS and 
PHLIS. 
Botulism surveillance has unique attributes. Botulism is an extreme hazard that can be fatal if 
untreated, and it has caused rare but catastrophic foodborne outbreaks that are public health 
emergencies. CDC provides the antitoxin used to treat the illness and releases it for treatment of 
suspected botulism from airport quarantine stations at the request of a state epidemiologist. 
Clinicians who suspect a patient has botulism can call their state health department or CDC to 
arrange release through a 24-hour emergency response system. This drug release mechanism 
means that CDC gets immediate information about suspected cases of botulism, which 
functions as an early alert surveillance system. 
Though not formally part of a surveillance system, EDEB tracks the number and type of non-
O157 Shiga toxin-producing E. coli received from public health laboratories around the 
39 
country. Among public health and clinical laboratories in the United States, only CDC has the 
capacity to serotype and characterize a wide variety of these isolates. Thus, our collection of 
isolates is likely representative of those isolated in the United States. and forwarded to public 
health laboratories. 
Surveillance at Selected Sites 
For nine foodborne infections, the most detailed and accurate surveillance information comes 
from the Foodborne Diseases Active Surveillance Network (FoodNet). In 2004, FoodNet 
included 10 surveillance sites, each comprised of several counties within a state, or a whole 
state, and covering a population of approximately 44.5 million, or 15% of the U.S. population. 
FoodNet actively gathers information about nine infections or conditions, integrates it with 
available laboratory information, and also collects information about the severity and outcome 
of the illness. In addition, FoodNet conducts population surveys to determine the burden of 
illness and how many ill persons visited a physician and got tested, as well as surveys of 
clinical laboratories to determine which pathogens are sought. Because standard surveillance 
methods are used, FoodNet data can be used to compare rates of illness over time and from one 
site to another. 
Enhancements to Surveillance Systems 
Public health surveillance is an evolving effort. As new disease entities are identified and 
defined as public health problems, surveillance for them begins and improves. As better 
understanding leads to better prevention, cases may level off, decline, and ultimately disappear. 
On the list of nationally notifiable diseases, there are several that were once large public health 
problems, but are now rarely reported. The official list of nationally notifiable diseases changes 
in accordance with resolutions issued by CSTE. 
The methods and information obtained for surveillance also continue to evolve. Active 
surveillance in sentinel populations (such as FoodNet) can provide reliable and detailed 
information about detected infections and eliminate the undercount caused by lack of resources 
or reporting effort. However, this effort is expensive and cannot be applied everywhere. The 
ongoing revolution in biotechnology is bringing new subtyping and fingerprinting technologies, 
such as pulsed-field gel electrophoresis (PFGE), into state and local public health laboratories. 
PulseNet is a national network of public health and food regulatory agency laboratories 
coordinated by CDC; PulseNet participants use PFGE to characterize isolates of foodborne 
disease pathogens. Isolate DNA patterns generated by PFGE are submitted electronically to the 
PulseNet database at CDC, where they are analyzed to identify clusters of illness caused by the 
same pathogen subtype. This approach is enhancing our capacity to detect outbreaks rapidly, to 
link widely separated cases, and to track more precisely the results of specific control measures. 
New electronic reporting media have accelerated reporting and have made possible practical 
automated cluster detection algorithms, such as the Statistical Outbreak Detection Algorithm 
(SODA), which has been in operation using PHLIS data for Salmonella since 1995. CDC’s 
efforts to produce a new integrated surveillance system, which will bring information directly 
from the clinical laboratory into a public health database, should improve the timeliness and 
consistency of reporting for many diseases.  
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Sources and Contacts for Bacterial Foodborne and Diarrheal 
Diseases 
Many staff members, both within and outside EDEB, are responsible for national surveillance 
for foodborne and diarrheal diseases. For the purpose of this report, EDEB national case 
surveillance activity is considered separate from foodborne outbreak surveillance, which is 
collected by FoodNet and the National Antimicrobial Resistance Monitoring System for 
Enteric Bacteria (NARMS-EB). Information about FoodNet and NARMS is available in the 
reference section. Surveillance for foodborne disease outbreaks is available in a report 
produced by the EDEB Outbreak Response and Surveillance Team. EDEB activities also 
include surveillance of bacterial pathogens. Surveillance information on viral diseases is 
reported by CDC’s Division of Viral and Rickettsial Diseases, while information on parasitic 
diseases is reported by the Division of Parasitic Diseases. Surveillance information on chemical 
intoxications is reported by CDC’s National Center for Environmental Health. 
Sources and Contacts for Bacterial Foodborne and Diarrheal Diseases 
System Cases Reported Contact Title CDC Division 
NNDSS/NETSS Clinical-case reporting of 
Campylobacteriosis, 
Botulism, STEC, Hemolytic 
Uremic Syndrome, 
Listeriosis, Typhoid Fever, 
Salmonellosis, Shigellosis, 
Cholera 
Ruth Ann Jajosky Epidemiologist Integrated Surveillance 
Systems and Services 
PHLIS Laboratory-based reporting 
of STEC, Salmonella, 
Shigella 






Detail case information for 
all U.S. botulism cases, 
including foodborne, infant, 
wound, and other forms 





Detailed case information for 
all U.S. typhoid fever cases 





Detailed case information for 
all U. S. cholera and other 
Vibrio species. infections 
Martha Iwamoto 
(vibriosis) 




Foodborne, Bacterial and 
Mycotic Diseases







Isolates received at CDC for 
serotyping and 
characterization 
Patricia Fields Chief, Enteric Diseases 
Laboratory Branch 
Foodborne, Bacterial and 
Mycotic Diseases 





Isolates received at CDC for 
serotyping and 
characterization 
Nancy Strockbine Team Lead, National 
E. coli, Shigella, 
Yersinia, and Vibrio 
Reference Lab 




List of Acronyms 
BSO………………. . Biostatistics Office 
CDC………………... Centers for Disease Control and Prevention 
CSTE……………….. Council of State and Territorial Epidemiologist 
DFBMD…………… Division of Foodborne, Bacterial and Mycotic Diseases 
EHEC………………. Enterohemorrhagic Escherichia coli 
EIA…………………. Enzyme Immunoassays 
ETEC………………..Enterotoxigenic Escherichia coli 
EDEB………………. Enteric Diseases Epidemiology Branch 
FDA…………………Food and Drug Administration 
FoodNet……………..Foodborne Diseases Active Surveillance Network 
HUS…………………Hemolytic Uremic Syndrome 
MMWR…………….. Morbidity Mortality Weekly Report 
NARMS-EB………... National Antimicrobial Resistance Monitoring System for Enteric Bacteria 
NCID……………….. National Center for Infectious Diseases 
NETSS……………... National Electronic Telecommunications System for Surveillance 
NNDSS…………….. National Notifiable Diseases Surveillance System 
PCR………………… Polymerase Chain Reaction 
PFGE……………….. Pulsed-field Gel Electrophoresis 
PHLIS……………… Public Health Laboratory Information System 
SODA………………. Statistical Outbreak Detection Algorithm 
STEC……………….. Shiga toxin-producing Escherichia coli 
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CDC Internet Sites Relevant to Foodborne and Diarrheal Diseases 
For more information about foodborne disease, please visit any of the following Web sites: 
Case definition for Infectious Conditions under Public Health Surveillance 
http://www.cdc.gov/epo/dphsi/casedef/index.htm 
Causes of Foodborne Illness 
http://www.cdc.gov/foodborneoutbreaks/foodborne_az.htm 
Division of Bacterial and Mycotic Diseases 
http://www.cdc.gov/ncidod/dbmd/ 
Division of Parasitic Diseases 
http://www.cdc.gov/ncidod/dpd/ 
DPDx (Identification and Diagnosis of Parasites of Public Health Concern) 
http://www.dpd.cdc.gov/dpdx/ 
Division of Viral and Rickettsial Diseases 
http://www.cdc.gov/ncidod/dvrd/index.htm 
Division of Viral Hepatitis 
http://www.cdc.gov/ncidod/diseases/hepatitis/index.htm 
Epidemiology Program Office, Division of Public Health Surveillance and Informatics 
http://www.cdc.gov/epo/index.htm 
Foodborne and Diarrheal Diseases Branch 
http://www.cdc.gov/ /foodborne/ 
Foodborne and Diarrheal Diseases Branch, Outbreak Response and Surveillance Team 
http://www.cdc.gov/foodborneoutbreaks/ 
FoodNet (Foodborne Diseases Active Surveillance Network) 
http://www.cdc.gov/foodnet/ 
NARMS: Enteric Bacteria (National Antimicrobial Resistance Monitoring System) 
http://www.cdc.gov/narms/ 
National Center for Infectious Diseases 
http://www.cdc.gov/ncidod/ 
PHLIS (Public Health Laboratory Information System) Surveillance Data 
http://www.cdc.gov/ncidod/dbmd/phlisdata/ 
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Public Health Practice Program Office (PHPPO) 
http://www.phppo.cdc.gov/index.asp 
PulseNet (National Molecular Subtyping Network for Foodborne Disease Surveillance) 
http://www.cdc.gov/pulsenet/ 
Respiratory and Enteric Virus Branch 
http://www.cdc.gov/ncidod/dvrd/revb/index.htm 
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